Navigation Links
Tramiprosate (Alzhemed? preclinical results published in Neurobiology of Aging

North American Phase III clinical trial will be offered the opportunity to receive tramiprosate (Alzhemed? in an open-label extension study.

Neurochem is also actively advancing an 18-month Phase III clinical trial for tramiprosate (Alzhemed? in Europe, which was initiated in September 2005. The ongoing European Phase III clinical trial, an international, multi-center, randomized, double-blind, placebo-controlled and parallel-designed study, is progressing on schedule and will investigate the safety, efficacy and disease-modifying potential of tramiprosate (Alzhemed?. Some 930 mild-to-moderate AD patients are expected to take part and enrollment is expected to be completed in the fall of 2006.

About Alzheimer's disease
Alzheimer's disease (AD) is a progressive form of dementia associated with specific brain pathologies. It impairs a person's cognitive and motor functions, their activities of daily living, alters the behaviour and gradually destroys the brain.

AD is the most common cause of dementia in our aging population. Almost 5 million individuals in the United States alone currently suffer from the condition. The U.S. Alzheimer's Association estimates that by 2025, over 22 million people worldwide will be afflicted.

According to a report commissioned by the U.S. Alzheimer's Association, AD costs American businesses approximately US$61 billion a year. That price tag includes US$24.6 billion for direct health care of Alzheimer's patients and US$36.5 billion to cover costs related to caregivers of AD patients, including lost productivity, absenteeism and worker replacement.


'"/>

Source:Neurochem, Inc.


Page: 1 2 3

Related biology news :

1. Fatty spheres loaded with siRNA shrink ovarian cancer tumors in preclinical trial
2. Dual gene therapy suppresses lung cancer in preclinical test
3. Gene vaccine for Alzheimers disease shows promising results
4. Roche clinical trial registry and results database launched
5. Diabetic nerve therapy shows striking results
6. Neurologix announces positive results of gene therapy clinical trial in Parkinsons disease
7. New results validating Pall prion reduction filter disclosed at ISBT Congress
8. Combination therapy shows promising results in patients with advanced lung cancer
9. Vaccine for brain tumors shows promising results
10. Artificial cornea offers better results for infants, some blind patients
11. Encouraging results in pancreatic cancer research
Post Your Comments:
(Date:7/29/2014)... cell, including sperm, bacteria and algae, propel themselves ... about one-hundredth of a millimetre long, function like ... shorter structures called cilia are found on the ... such as moving liquids over the cell. ... transport mucus and expel pathogens from our airways, ...
(Date:7/28/2014)... An international team of researchers led by the University ... rice. , The genetic information will enhance scientists, and ... as well as enable the development of new rice ... environmental stressors to help solve global hunger challenges. , ... Oryza glaberrima ) and evidence for independent domestication," was ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... cancer has shown considerable promise in early clinical trials ... drugs. Chemists and biologists at ... Sloan-Kettering Cancer Center, have created a new drug to ... as castration-resistant prostate cancer, or CRPC. Also referred to ...
... of drug-resistant bacteria, called multidrug-resistant gram-negative (MDRGN) ... common antimicrobial-resistant infections in long-term care facilities, ... at Hebrew SeniorLife,s Institute for Aging Research., ... of the main reservoirs of antimicrobial-resistant bacteria. ...
... /PRNewswire-Asia/ -- Futronic Technology Company,Limited, a global provider of ... of FS90 USB2.0 Mini Fingerprint,Scanner. , ... deliver high quality image,in a very small form factor. ... and just,slightly larger than one half of Futronic FS80 ...
Cached Biology News:New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Study finds multidrug-resistant gram-negative bacteria high in long-term care 2Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner 2
(Date:7/29/2014)... Cheshire Cat: Can a particle be separated from its ... Communications , published the results of the first Cheshire ... conducted by Chapman University in Orange, CA, and Vienna ... a cat without a grin," thought Alice in Wonderland, ... curious thing I ever saw in my life!" Alice,s ...
(Date:7/29/2014)... YORK , July 29, 2014  Pomerantz LLP ... Laboratories, Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... of its officers and/or directors have violated Sections 10(b) ... On July 29, 2014, Impax Laboratories, ...
(Date:7/29/2014)... Calif. , July 29, 2014 /PRNewswire-iReach/ -- ... agreement with FORMA Therapeutics, Inc., to provide access ... proprietary fragment-based lead discovery platform for novel small ... excited about the opportunity to work with FORMA ... of epigenetics and protein homeostasis. FORMA Therapeutics, decision ...
(Date:7/29/2014)... TransVac Solutions, the trusted leader in ... solutions for hospitals, will be exhibiting at booth #209 ... Conference & Technical Exhibition Aug. 3-6 in Chicago, Ill. ... making hospitals cleaner, reducing infection risk and saving millions ... cycle. Staff will be available at booth #209 ...
Breaking Biology Technology:The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2
... DJO Incorporated,(NYSE: DJO ), a global provider of ... reported that on August 9, 2007,the U.S. Federal Trade ... the Hart-Scott-Rodino Antitrust Improvements Act of,1976, as amended, for ... Therapeutics, Inc. ("ReAble"). On July 16, 2007, DJO ...
... Valeant Pharmaceuticals ... ... Biosciences,Inc. (Pink Sheets: ARDC) today announced that it has received the ... (NYSE: VRX ). In December 2006, Ardea Biosciences entered ...
... Shareholder Support for Vermed Sale, SAN DIEGO, Aug. ... innovator and leader of,impedance cardiography (ICG) technology, today announced ... progressing well with over 50%,of the necessary shareholder votes ... the Vermed sale. The ratio of votes,received is running ...
Cached Biology Technology:DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 2DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 3DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review 4Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc. 2CardioDynamics Provides 2007 Shareholder Meeting Update 2CardioDynamics Provides 2007 Shareholder Meeting Update 3
HOXC11 Antibody...
Anti-NeuroD 6 Immunogen: Synthetic peptide. Available Date: 36708...
HOXC11 Antibody...
Anti-MMP-14, catalytic domain, clone LEM-2/15.8 Immunogen: Synthetic peptide: amino acid sequence 218-233 within the catalytic domain Available Date: 38579...
Biology Products: